+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Colorectal Cancer Therapeutics Market 2019-2023 - Product Image

Global Colorectal Cancer Therapeutics Market 2019-2023

  • ID: 4756177
  • Report
  • February 2019
  • Region: Global
  • 128 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Sanofi
  • MORE
The global colorectal cancer therapeutics market is largely dominated by monotherapy drugs, including targeted therapies and immunotherapies. However, the combination of these monotherapy drugs with chemotherapy or other therapeutics also increases the therapeutic value. The combination of drugs helps in overcoming the limitations of each therapeutic and increases the overall outcome in the treatment of colorectal cancer. Furthermore, the combination of therapies with or without surgery can be used to reduce the spreading of the disease and temporarily shrink a cancerous tumor. Moreover, the combination therapy that contains two or more number of therapeutics is useful to achieve an additive or synergistic effect with low doses of combinational therapeutics. The analysts have predicted that the colorectal cancer therapeutics market will register a CAGR of almost 3% by 2023.

Market Overview

Rising population with risk factors of colorectal cancer

The incidence of colorectal cancer is increasing owing to the risk factors such as the increasing geriatric population, inflammatory diseases, genetic syndromes, and changes in lifestyle. Hence, an increase in the number of patients with these risk factors is expected to increase the development of colorectal cancer. This, in turn, is expected to aid in the use of available therapeutics, which will drive the growth of the global colorectal cancer therapeutics market during the forecast period.

Patent expiration of novel therapeutics

The pharmaceutical companies sell their innovator products, especially biologics, at a high price until their patent expiration. The expiration of patents and other intellectual property rights of therapeutics are likely to hamper the growth of the global colorectal cancer therapeutics market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the colorectal cancer therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fairly concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Targeted therapy - Market size and forecast 2018-2023
  • Immunotherapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sanofi
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 21: Targeted therapies in Phase III for colorectal cancer treatment
Exhibit 22: Immunotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Immunotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Colorectal cancer rate based on gender in US 2015
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Rate of colorectal cancer by age in the US
Exhibit 46: Global geriatric population
Exhibit 47: Combination therapies for colorectal cancer treatment
Exhibit 48: Late-stage combination therapies for treatment of colorectal cancer
Exhibit 49: Estimated patent expiry dates of a few therapeutics used for colorectal cancer treatment
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Some of the kinase inhibitors under development for colorectal cancer treatment
Exhibit 52: Vendor landscape
Exhibit 53: Landscape disruption
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors 0
Exhibit 57: Bristol-Myers Squibb Company - Vendor overview 1
Exhibit 58: Bristol-Myers Squibb Company - Business segments 1
Exhibit 59: Bristol-Myers Squibb Company - Organizational developments 2
Exhibit 60: Bristol-Myers Squibb Company - Geographic focus 3
Exhibit 61: Bristol-Myers Squibb Company - Key offerings 4
Exhibit 62: Bristol-Myers Squibb Company - Key customers 4
Exhibit 63: Eli Lilly and Company - Vendor overview 5
Exhibit 64: Eli Lilly and Company - Business segments 5
Exhibit 65: Eli Lilly and Company - Organizational developments 6
Exhibit 66: Eli Lilly and Company - Geographic focus 7
Exhibit 67: Eli Lilly and Company - Segment focus 7
Exhibit 68: Eli Lilly and Company - Key offerings 7
Exhibit 69: Eli Lilly and Company - Key customers 8
Exhibit 70: F. Hoffmann-La Roche Ltd - Vendor overview 9
Exhibit 71: F. Hoffmann-La Roche Ltd - Business segments 9
Exhibit 72: F. Hoffmann-La Roche Ltd - Organizational developments 0
Exhibit 73: F. Hoffmann-La Roche Ltd - Geographic focus 1
Exhibit 74: F. Hoffmann-La Roche Ltd - Segment focus 1
Exhibit 75: F. Hoffmann-La Roche Ltd - Key offerings 2
Exhibit 76: F. Hoffmann-La Roche Ltd - Key customers 2
Exhibit 77: Merck & Co., Inc. - Vendor overview 3
Exhibit 78: Merck & Co., Inc. - Business segments 3
Exhibit 79: Merck & Co., Inc. - Organizational developments
Exhibit 80: Merck & Co., Inc. - Geographic focus
Exhibit 81: Merck & Co., Inc. - Segment focus
Exhibit 82: Merck & Co., Inc. - Key offerings
Exhibit 83: Merck & Co., Inc. - Key customers
Exhibit 84: Sanofi - Vendor overview
Exhibit 85: Sanofi - Business segments
Exhibit 86: Sanofi - Organizational developments
Exhibit 87: Sanofi - Geographic focus
Exhibit 88: Sanofi - Segment focus
Exhibit 89: Sanofi - Key offerings
Exhibit 90: Sanofi - Key customers
Exhibit 91: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Sanofi
  • MORE
Global Colorectal Cancer Therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global colorectal cancer therapeutics market: Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of small molecules kinase inhibitors.”

According to the report, one of the major drivers for this market is the rising population with risk factors of colorectal cancer.

Further, the report states that one of the major factors hindering the growth of this market is the side effects associated with availability medicines.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll